MDM4 and breast carcinoma: By evaluating the impact of the alleles of MDMX SNP34091 on the event-free survival in breast cancer patients, we found that A/A-patients had an average time until recurrence of 77.1 months compared with 67.3 months for C/C-patients (p = 0.219; log-Rank-test; Supplementary Table 11).